Global Pantothenate Kinase Associated Neurodegeneration (PKAN) Market, By Form (Classic, Atypical), Diagnostic Test (Genetic Tests, MRI Scan, Others), Treatment (Anti-Convulsive Drugs, Drugs on Dystonia, Other Supportive Treatment), End-User (Hospitals, Academic and Research Institutes, Private Clinics, Others) - Industry Trends and Forecast to 2030.
Pantothenate Kinase associated Neurodegeneration (PKAN) Market Analysis and Size
Pantothenate kinase associated neurodegeneration (PKAN) is a rare, inherited neurological movement disorder characterized by the progressive degeneration of specific regions in the central nervous system. It is usually diagnosed with the help of molecular genetic testing after a trait finding on magnetic resonance imaging (MRI), called the “eye-of-the-tiger” sign.
Data Bridge Market Research analyses that the pantothenate kinase associated neurodegeneration (PKAN) market is expected to undergo a CAGR of 6.5% during the forecast period of 2023 to 2030. “Classical” dominates the form segment of the Pantothenate Kinase associated Neurodegeneration (PKAN) market owing to the rise in the geriatric population. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Pantothenate Kinase associated Neurodegeneration (PKAN) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Form (Classic, Atypical), Diagnostic Test (Genetic Tests, MRI Scan, Others), Treatment (Anti-Convulsive Drugs, Drugs on Dystonia, Other Supportive Treatment), End-User (Hospitals, Academic and Research Institutes, Private Clinics, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa
|
|
Market Players Covered
|
|
|
Market Opportunities
|
|
Market Definition
A subset of diseases known as Neurodegeneration with Brain Iron Accumulation (NBIA), Pantothenate Kinase associated Neurodegeneration (PKAN) is an uncommon hereditary ailment. It is characterized by the buildup of iron in particular brain parts, which causes a steady decline in neurological abilities. Mutations in the PANK2 gene, which creates the pantothenate kinase enzyme, are the root cause of PKAN. This enzyme is important for synthesizing coenzyme A (CoA), which is necessary for several cellular functions. When pantothenate kinase is absent or inactive, CoA production is hindered, which causes the buildup of toxins in the brain and ensuing neurodegeneration.
Pantothenate Kinase associated Neurodegeneration (PKAN) Market Dynamics
Drivers
- Increasing prevalence of PKAN
Even though PKAN is a rare disorder, uncommon diseases are becoming more common worldwide. It is anticipated that there will be more diagnosed cases of PKAN as knowledge and diagnostic tools advance. The need for PKAN-related goods and services, including diagnostics, therapies, and supportive care, is driven by this expanding patient population.
- Increasing technological advancements
The PKAN industry is driven by technological developments in several industries, including drug development, neuroimaging, and genetic testing. These developments make it possible to develop novel medicines, more accurate and accessible diagnostic techniques, and a better knowledge of how diseases work. For instance, improvements in gene editing and delivery technologies could completely alter the range of available PKAN treatments.
- Increasing improvement in healthcare infrastructure
Greater chances for detecting and treating uncommon disorders such as PKAN are made possible by improvements in the healthcare infrastructure, particularly in emerging economies. The availability of specialized healthcare specialists, cutting-edge diagnostic equipment, and supportive care services increases, which boosts consumer demand for PKAN-related goods and services.
Opportunities
- Growing research & development activities
New treatment options may become available due to continued investigation into the pathophysiology of PKAN and the discovery of possible therapeutic targets. Creating novel medications and interventions can be sped up through increased preclinical and clinical research spending and cooperative initiatives between academics, businesses, and advocacy groups.
- Rising development of targeted therapies
A sizable opportunity exists in the PKAN market due to the investigation of targeted medicines such as gene therapies, enzyme replacement therapies, and iron chelation therapies. The underlying genetic and metabolic problems linked to PKAN may be addressed by improvements in these therapeutic techniques, improving outcomes for those affected.
- Increasing strategic initiatives by the key market players
The development of the PKAN industry depends heavily on cooperation between several parties, including pharmaceutical corporations, research institutes, advocacy groups, and regulatory authorities. Collaboration can speed up research, encourage innovation, and make developing, approving, and marketing PKAN-related goods and services easier.
Restrains
- Strict regulations
Obtaining regulatory authorization for innovative treatments for uncommon diseases can be difficult and time-consuming. Although there are issues with orphan drug classifications, clinical trial requirements, and market access, the regulatory environment for rare diseases is changing. Companies creating PKAN medicines may face difficulties navigating these regulatory barriers, which could slow innovation and market access.
- High treatment cost
Due to the limited patient population and the complex nature of rare disorders like PKAN, developing medicines can be expensive. For healthcare systems, insurers, and patients, treatments may be financially expensive due to the high research, development, and production cost. Concerns with affordability and reimbursement may hamper access to cutting-edge medicines for people with PKAN.
Challenges
- Limited accessibility for the treatment
Particularly in some geographical areas or nations with limited resources, access to specialized healthcare facilities, diagnostic equipment, and therapies for PKAN may be constrained. Access for people with PKAN may be hampered by the high expense of specialized care, genetic testing, and supportive treatments, resulting in inequities in healthcare and unequal treatment options.
- Disease Complexity
Because PKAN is a complicated condition with significant clinical heterogeneity, it is difficult to comprehend its underlying mechanisms and create effective treatments. Personalized techniques, which can be challenging to implement on a broad scale because of the diversity in disease presentation, development, and response to medicines, are necessary. PKAN complicates the clinical trial design, outcome measurement, and development standardised treatment regimens.
This pantothenate kinase associated neurodegeneration (PKAN) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pantothenate kinase associated neurodegeneration (PKAN) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Pantothenate Kinase associated Neurodegeneration (PKAN) Market Scope
Pantothenate kinase associated neurodegeneration (PKAN) market is segmented based on form, diagnostic test, treatment and end-user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Form
- Classic
- Atypical
Diagnostic test
- Genetic Test
- MRI scan
- Others
Treatment
- Anti-convulsive drugs
- Drugs on dystonia
- Other supportive treatment
End-User
- Hospitals
- Academic and research institutes
- Private clinics
- Others
Pantothenate Kinase associated Neurodegeneration (PKAN) Market Regional Analysis/Insights
Pantothenate kinase associated neurodegeneration (PKAN) market is analyzed and market size information is provided by country by form, diagnostic test, treatment and end-user as referenced above.
The countries covered in the pantothenate kinase associated neurodegeneration (PKAN) market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America is expected to dominate the pantothenate kinase associated neurodegeneration (PKAN) market due to the rapid technological advancements, better reimbursement policies, and strong presence of key players.
Asia-Pacific region is expected to expand at a significant growth rate in the forecast period of 2023 to 2030 because of the rise in awareness among people regarding various neurological conditions and government initiatives.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
Pantothenate kinase associated neurodegeneration (PKAN) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Pantothenate Kinase associated Neurodegeneration (PKAN) Market Share Analysis
Pantothenate kinase associated neurodegeneration (PKAN) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to the market.
Some of the major players operating in the pantothenate kinase associated neurodegeneration (PKAN) market are:
- Johnson & Johnson Services Inc (U.S.)
- Abbott (U.S.)
- Novartis AG (Switzerland)
- Sanofi (France)
- Pfizer, Inc. (U.S.)
- BD (U.S.)
- Allergan (U.S.)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Biogen (U.S.)
- Merz Pharma (Germany)
- AstraZeneca (U.K.)
- Sun Pharmaceutical Industries Ltd. (India)
- Ipsen Pharma (France)
- Merck & Co, Inc. (U.S.)
- Revance Therapeutics Inc. (U.S.)
- Aspen Holdings (South Africa)
- Boston Scientific Corporation (U.S.)
- GlaxoSmithKline plc (U.K.)
- Eisai Co., Ltd. (Japan)
SKU-